Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.Abstract Background Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) provides 24‐h delivery of levodopa‐carbidopa prodrugs for advanced Parkinson's disease. Real‐world 1‐year European data remain limited. Objectives To characterize 1‐year changes in motor, non‐motor, autonomic, quality‐of‐life and sleep outcomes, and in concomitant therapy ...
Mario Hero +5 more
wiley +1 more source
Differential expression of striatal proteins in a mouse model of DOPA-responsive dystonia reveals shared mechanisms among dystonic disorders. [PDF]
Mol Genet Metab, 2021 Briscione MA +9 more
europepmc +1 more source
Perinatal Post‐Anoxic Spinal Cord Injury: A Barrier to Pallidal Neuromodulation? About 2 Cases
Movement Disorders Clinical Practice, EarlyView.
Marylou Grasso +4 more
wiley +1 more source
Paroxysmal Dystonic Choreoathetosis
, 2000 The clinical characteristics of paroxysmal dystonic choreoathetosis (PDC) in 20 affected members of a large British family are reported from the Institute of Neurology, Queen Square, and the MR Unit, Hammersmith Hospital, London ...
J Gordon Millichap
core +1 more source
Progress on magnetic resonance-guided focused ultrasound in the treatment of movement disorders
Chinese Journal of Contemporary Neurology and NeurosurgeryMagnetic resonance-guided focused ultrasound (MRgFUS) has been increasingly applied to the treatment of movement disorders in recent years as a non-invasive, real-time and precise neuromodulation technology.
ZHOU Mei-tong +3 more
doaj +1 more source
Doenças do movimento induzidas por fármacos: a importância dos psicofármacos.
Acta Médica Portuguesa, 2011 This article reviews the current knowledge on drug-induced movement disorders (DIMD) epidemiology, pathophysiology, phenomenology and treatment. This review is justified by its high prevalence in certain medical specialties, the need to include them on ...
Joana Damásio, Serafim Carvalho
doaj +1 more source
JAK2 Variant and Parkinsonian Syndromes: Coincidence or Pathophysiological Link?
Movement Disorders Clinical Practice, EarlyView.Abstract Background JAK2 variants are a hallmark of myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythemia. These disorders are often associated with thrombotic and inflammatory complications. From a movement disorder perspective, chorea is a rare but well‐recognized neurological occurrence in this context ...
Elena Ardila Jurado +5 more
wiley +1 more source
Advances in deep brain stimulation for movement disorders
Chinese Journal of Contemporary Neurology and NeurosurgeryAs an established neuromodulation technique, deep brain stimulation (DBS) is widely used in the treatment of movement disorders, including Parkinson's disease (PD), essential tremor (ET) and dystonia.
MENG Xia-yu +4 more
doaj +1 more source
Tardive Dystonia: Clinical Spectrum and Novel Manifestations
Behavioural Neurology, 1988 Tardive dystonia was identified in 25 patients: involvement of the face and neck was most common; truncal and limb dystonia were also observed. There were 3 cases of laryngospasm and 2 of spasmodic dysphonia.
R. Jeffrey Davis +2 more
doaj +1 more source
Central Nervous System Tumors in Xeroderma Pigmentosum: Five Cases and Review of the Literature
Movement Disorders, EarlyView.Abstract Background Xeroderma pigmentosum (XP) is a rare autosomal recessive DNA‐repair disorder characterized by extreme ultraviolet radiation (UVR) sensitivity, markedly increased cutaneous malignancy risk, and progressive neurological disease in approximately one‐third of patients.
Farrah S. Bakr +4 more
wiley +1 more source